Profusa and Mayo Clinic Collaborate to Commercialize $100M-Backed Lumee Oxygen Sensor for Chronic Limb Ischemia
Profusa signed a know-how agreement with Mayo Clinic to accelerate regulatory approval and US commercialization of Lumee continuous tissue oxygen sensors for chronic limb threatening ischemia and explore cardiovascular, renal, multi-organ and orthopedic applications. Backed by over $100 million in development funding, Lumee provides real-time intra-organ perfusion data.
1. Collaboration Details
Profusa entered a know-how agreement with Mayo Clinic to investigate high-impact clinical applications of its oxygen monitoring technologies, targeting cardiovascular, renal, multi-organ and orthopedic indications. The deal aims to accelerate regulatory approval and US commercialization of Lumee sensors for chronic limb threatening ischemia.
2. Lumee Technology and Development
The Lumee platform, backed by over $100 million in development funding, enables continuous, real-time tissue oxygen measurement directly within the body. Profusa plans to leverage this disruptive biosensor technology to expand its market reach and enhance disease management through earlier detection and improved clinical outcomes.